Home / Deep Research / CRX-Related Retinopathy

CRX-Related Retinopathy

1. Disease Information

2026-07-07
Falcon MONDO:1040064 Model: Edison Scientific Literature 32 citations

1. Disease Information

Overview

CRX-related retinopathy encompasses a spectrum of inherited retinal diseases caused by mutations in the CRX (Cone-Rod Homeobox) gene, located on chromosome 19q13.33. CRX encodes a 299 amino acid homeodomain transcription factor essential for photoreceptor development, function, and maintenance (sun2023geneaugmentationfor pages 1-3, zheng2024transcriptionalprecisionin pages 1-2). CRX is the only gene known to be associated with all three major forms of inherited retinal degeneration: Leber congenital amaurosis (LCA), cone-rod dystrophy (CoRD), and retinitis pigmentosa (RP) (zheng2024transcriptionalprecisionin pages 1-2). The clinical spectrum ranges from mild adult-onset macular dystrophy to severe congenital blindness (sun2023geneaugmentationfor pages 1-3).

Key Identifiers

  • OMIM: Leber Congenital Amaurosis 7 (LCA7, OMIM #602225); Cone-Rod Dystrophy 2 (CoRD2, OMIM #120970); CRX Gene (OMIM *602225)
  • Orphanet: ORPHA:71965 (LCA); ORPHA:1872 (Cone-rod dystrophy)
  • ICD-10: H35.5 (Hereditary retinal dystrophy)
  • Chromosomal location: 19q13.33
  • Gene: CRX (HGNC:2383; NCBI Gene: 1406)

Synonyms

  • CRX-associated retinal dystrophy
  • CRX-associated retinopathy
  • Leber congenital amaurosis type 7 (LCA7)
  • Cone-rod dystrophy type 2 (CoRD2, CORD2)
  • CRX-related cone-rod dystrophy
  • CRX-related macular dystrophy

2. Etiology

Disease Causal Factors

CRX-related retinopathy is a Mendelian genetic disease caused by mutations in the CRX gene. To date, 93 disease-causing CRX mutations have been identified, and the ClinVar database documents 338 total CRX coding variants, of which 80 are classified as pathogenic or likely pathogenic, 192 as variants of uncertain significance, and 77 as benign or likely benign (sun2023geneaugmentationfor pages 1-3, zheng2024transcriptionalprecisionin pages 4-6).

Genetic Risk Factors

The primary risk factor is inheritance of a pathogenic CRX variant. Most CRX disease variants arise de novo and are completely penetrant in heterozygotes, causing autosomal dominant disease (zheng2024transcriptionalprecisionin pages 4-6). Rare recessive presentations have also been documented, particularly with the R90W variant in homozygous state causing LCA (sun2023diseasecausingmutationsin pages 5-7, loukovitis2021areviewof pages 9-11). The de novo mutation rate for CRX has been estimated at approximately 10.34% among inherited eye disease trios, making it one of the top 10 genes with the highest de novo mutation burden (zheng2024transcriptionalprecisionin pages 4-6).

Environmental and Protective Factors

No specific environmental risk factors or protective factors have been identified for CRX-related retinopathy. As a purely monogenic disorder, environmental contributions to disease onset are not established. However, genetic background and modifier genes may influence expressivity, as significant phenotypic variability has been observed even within families sharing the same CRX variant (zheng2024transcriptionalprecisionin pages 4-6, loukovitis2021areviewof pages 9-11).

3. Phenotypes

Clinical Presentations

CRX-related retinopathy presents with considerable phenotypic variability, encompassing several distinct clinical entities (sun2023geneaugmentationfor pages 1-3, lin2025bifocalretinaldegeneration pages 2-4):

Leber Congenital Amaurosis (LCA7) - Age of onset: Birth to early infancy (congenital/neonatal) - Severity: Severe; poor visual acuity starting within the first year of life - Phenotype: Severe early-onset blindness with cone-led retinal dystrophy; hyperopia is common - HPO terms: HP:0000510 (Rod-cone dystrophy), HP:0000548 (Cone-rod dystrophy), HP:0001103 (Abnormal macular morphology), HP:0000505 (Visual impairment) - Frequency: CRX accounts for 0.6–2.35% of LCA cases (winkler2020largeanimalmodels pages 12-14)

Cone-Rod Dystrophy (CoRD2) - Age of onset: Variable (childhood to late adult onset depending on variant) - Severity: Variable; ranges from mild macular dysfunction to severe bilateral visual loss - Progression: Progressive; cone degeneration typically precedes rod degeneration - HPO terms: HP:0000548 (Cone-rod dystrophy), HP:0007754 (Macular dystrophy), HP:0000572 (Visual loss)

Retinitis Pigmentosa (RP) - Age of onset: Variable (typically later onset than LCA) - Severity: Variable - HPO terms: HP:0000510 (Rod-cone dystrophy), HP:0000546 (Retinal degeneration)

Macular Dystrophy - Age of onset: Typically adult-onset - Severity: Mild to moderate - HPO terms: HP:0007754 (Macular dystrophy)

Distinctive Phenotypic Features

A recent study of 60 patients with molecularly confirmed CRX-associated retinopathy identified a distinctive bifocal retinal degeneration pattern in approximately 12% of cases (all male), characterized by central retinal degeneration combined with a discrete non-contiguous area of altered autofluorescence in the nasal periphery (lin2025bifocalretinaldegeneration pages 2-4, lin2025bifocalretinaldegeneration pages 6-7). This bifocal pattern is not typically seen in other forms of inherited retinal disease and can serve as a diagnostic clue (lin2025bifocalretinaldegeneration pages 6-7).

Electrophysiological Phenotype

All patients with bifocal degeneration demonstrated bilaterally subnormal PERG P50 responses indicating severe macular dysfunction. Full-field ERG patterns showed either pure cone dysfunction (2/6 cases), cone greater than rod dysfunction (3/6), or similar cone-rod involvement (1/6), with markedly delayed b-waves in most cases, consistent with a post-phototransduction locus of dysfunction (lin2025bifocalretinaldegeneration pages 2-4).

4. Genetic/Molecular Information

Causal Gene: CRX

Pathogenic Variant Classification

CRX disease variants have been systematically classified into four major classes based on their functional impacts, as detailed in the following table (zheng2024transcriptionalprecisionin pages 6-7, zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8):

Table (click to expand)
Variant class Representative variant(s) ClinVar ID / identifier Primary molecular mechanism Effect on CRX protein function Mouse / model phenotype Associated human phenotype(s)
Truncated effector-domain variants E168d2; human c.503_504del (p.Glu168fs) VCV000099609 for E168d2 Premature termination in the C-terminal transcription effector domain; mutant transcript/protein overexpression increases mutant:wild-type ratio, producing a dominant-negative effect in which mutant CRX outcompetes WT CRX at cognate regulatory sites (zheng2024transcriptionalprecisionin pages 6-7) DNA-binding domain remains intact, but transcriptional activation is defective/incompetent because the effector domain is truncated; downstream photoreceptor gene activation is impaired (sun2023diseasecausingmutationsin pages 5-7, zheng2024transcriptionalprecisionin pages 6-7) E168d2/+ mice have 6-8 ONL rows by 3 months, no detectable cone function, severely impaired rod function by 1 month, and complete rod function loss by 3 months; E168d2/d2 mice retain only 3-4 ONL rows by 1 month and never develop visual function (zheng2024transcriptionalprecisionin pages 6-7) Dominant Leber congenital amaurosis (LCA7); severe early-onset retinal degeneration (sun2023diseasecausingmutationsin pages 5-7, zheng2024transcriptionalprecisionin pages 6-7)
Extended effector-domain variants CrxRip; spontaneous c.763del (p.Gly255Alafs*133) No ClinVar ID stated in gathered evidence Frameshift creates an elongated mutant CRX with partial effector domain plus non-homologous C-terminal extension; altered residue composition likely perturbs recruitment specificity/affinity for transcriptional cofactors and mediators, causing genome-wide misregulation (zheng2024transcriptionalprecisionin pages 6-7, zheng2024transcriptionalprecisionin pages 7-8) DNA-binding domain is preserved, but the altered/extended effector domain disrupts transcriptional regulation; proposed loss of OTX tail function and abnormal cofactor recruitment antagonize WT CRX (zheng2024transcriptionalprecisionin pages 6-7, zheng2024transcriptionalprecisionin pages 7-8) Rip/+ mice are completely blind at 1 month, yet ONL thickness is largely preserved up to at least 18 months, indicating profound functional impairment and incomplete differentiation without rapid structural degeneration (zheng2024transcriptionalprecisionin pages 6-7) Congenital blindness / LCA-like CRX-associated retinopathy; class exemplifies severe functional deficit with relatively preserved retinal thickness early on (sun2023geneaugmentationfor pages 3-4, zheng2024transcriptionalprecisionin pages 6-7)
Hypomorphic missense variants reducing DNA-binding affinity R90W (p.Arg90Trp); also R40, R41, R43 class variants VCV000007422 for R90W Reduced homeodomain DNA-binding affinity lowers CRX target-gene activation; severity generally tracks with the degree of deviation from wild-type DNA binding strength (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8) CRX binds cognate DNA poorly and transactivates photoreceptor promoters weakly; R90 contributes structural stabilization of the HD-DNA complex rather than direct base contact (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8) CrxR90W/W mice resemble Crx knockout photoreceptor degeneration phenotypes; loss of photoreceptor differentiation/function is consistent with markedly reduced DNA binding (zheng2024transcriptionalprecisionin pages 7-8) Recessive LCA and mild late-onset dominant cone-rod dystrophy; R40/R41/R43 variants are linked to more severe dominant retinal dystrophies (sun2023diseasecausingmutationsin pages 5-7, zheng2024transcriptionalprecisionin pages 7-8)
Antimorphic missense variants altering DNA-binding specificity / selectivity E80A (p.Glu80Ala); K88N (p.Lys88Asn) VCV000007416 for E80A; no ClinVar ID stated here for K88N Gain-of-function / antimorphic mechanisms. E80A preserves preference for CRX sites but reduces selectivity, promoting promiscuous binding and hyperactivation of early target genes; K88N alters DNA-binding specificity, redirecting CRX to ectopic non-cognate sites (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 10-11) E80A causes elevated transactivation at WT and suboptimal motifs; K88N changes preferred DNA sequence recognition from canonical CRX motifs toward alternative motifs, severely perturbing gene-expression programs (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 10-11) E80A/+ mice show no detectable cone-mediated responses, defective rod-mediated responses at 1 month, shortened/disorganized outer segments and ONL disorganization, but no obvious early photoreceptor degeneration; knock-in studies of E80A and K88N demonstrate severe dominant retinopathy through distinct gain-of-function mechanisms (zheng2024transcriptionalprecisionin pages 8-10, winkler2020largeanimalmodels pages 12-14) Severe early-onset dominant cone-rod dystrophy for E80A; severe dominant retinopathies including LCA/CoRD spectrum for E80A and K88N (sun2023geneaugmentationfor pages 1-3, sun2023diseasecausingmutationsin pages 5-7, winkler2020largeanimalmodels pages 12-14)

Table: This table summarizes the four major CRX pathogenic variant classes described in recent literature, linking representative mutations to molecular mechanisms, functional consequences, model phenotypes, and human disease presentations. It is useful for understanding genotype-mechanism-phenotype relationships across CRX-associated retinopathies.

Key Pathogenic Variants

Representative pathogenic variants include: - p.Glu168fs (c.503_504del; ClinVar VCV000099609): Truncated effector domain; dominant LCA (zheng2024transcriptionalprecisionin pages 6-7) - p.Gly255Alafs*133 (c.763del): Extended effector domain (CrxRip); congenital blindness (zheng2024transcriptionalprecisionin pages 6-7) - p.Arg90Trp (c.268C>T; ClinVar VCV000007422): Hypomorphic; recessive LCA / mild dominant CoRD (zheng2024transcriptionalprecisionin pages 7-8) - p.Glu80Ala (c.239A>C; ClinVar VCV000007416): Antimorphic gain-of-function; severe dominant CoRD (zheng2024transcriptionalprecisionin pages 7-8) - p.Lys88Asn: Antimorphic altered specificity; severe dominant retinopathy (zheng2024transcriptionalprecisionin pages 8-10) - p.Gln228Ter (c.682C>T): Nonsense; autosomal dominant CoRD with late onset and severe macular atrophy - p.Arg98Ter: Nonsense; associated with variable RP presentations (zheng2024transcriptionalprecisionin pages 15-15)

Inheritance Pattern

Functional Consequences

The ratio of mutant to wildtype CRX protein directly correlates with disease severity (sun2023diseasecausingmutationsin pages 5-7). Frameshift mutations in the last exon escape nonsense-mediated decay (NMD), leading to allelic-specific overexpression of mutant transcripts and accumulation of non-functional truncated proteins—a mechanism that increases the mutant-to-WT ratio and drives dominant-negative pathogenesis (zheng2024transcriptionalprecisionin pages 6-7).

5. Environmental Information

CRX-related retinopathy is a purely genetic condition with no established environmental risk factors, lifestyle contributors, or infectious agents. No gene-environment interactions have been described. The disease is determined entirely by the nature and functional impact of the CRX mutation.

6. Mechanism / Pathophysiology

Molecular Pathways

CRX operates as a master transcriptional regulator within the photoreceptor gene regulatory network. It belongs to the orthodenticle (OTX) gene family and is activated by OTX2 in photoreceptor precursors after cell cycle exit (sun2023diseasecausingmutationsin pages 1-2). CRX regulates gene expression through: - Chromatin remodeling: CRX binding capacity depends on nucleosome interactions and chromatin accessibility (zheng2024transcriptionalprecisionin pages 3-4) - Synergistic interaction with NRL: CRX and NRL co-occupancy of binding sites deforms DNA and facilitates transcriptional machinery access for rod-specific gene expression (zheng2024transcriptionalprecisionin pages 4-6) - Phase-separation capacity: CRX activates genes through phase-separation of its activation domains (zheng2024transcriptionalprecisionin pages 11-12) - Interaction with BCOR: The co-repressor BCOR modulates CRX/OTX2 transcriptional activity, reducing their ability to activate photoreceptor gene promoters (langouet2022mutationsinbcora pages 1-2)

GO terms: GO:0006355 (regulation of transcription, DNA-templated), GO:0007601 (visual perception), GO:0042462 (eye photoreceptor cell development), GO:0046530 (photoreceptor cell differentiation)

Cellular Processes

CRX dysfunction results in failure of photoreceptor terminal differentiation. In CRX-deficient retinas, photoreceptor cells are produced normally but phototransduction gene expression is reduced, leading to progressive degeneration (langouet2022mutationsinbcora pages 1-2). Disease progression characteristically shows cone photoreceptor degeneration preceding rod degeneration, with rods initially functional but progressively degenerating (sun2023diseasecausingmutationsin pages 5-7).

Pathogenic Mechanisms (Four Classes)

  1. Truncated effector domain variants (e.g., E168d2): Dominant-negative mechanism via overexpression of transcriptionally incompetent mutant CRX that outcompetes WT CRX at cognate DNA binding sites (zheng2024transcriptionalprecisionin pages 6-7)
  2. Extended effector domain variants (e.g., CrxRip): Altered amino acid composition of the effector domain disrupts recruitment specificity for transcriptional cofactors, causing genome-wide gene misregulation (zheng2024transcriptionalprecisionin pages 7-8)
  3. Hypomorphic missense variants (e.g., R90W): Reduced DNA binding affinity diminishes CRX-mediated transactivation; severity correlates with binding affinity deviation from WT (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8)
  4. Antimorphic missense variants (e.g., E80A, K88N): Gain-of-function mechanisms—E80A reduces DNA binding selectivity causing hyperactivation and developmental asynchrony; K88N alters DNA binding specificity redirecting CRX to ectopic sites (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 10-11)

Protein Dysfunction

The CRX homeodomain's N-terminal residues make specific contacts with DNA bases in the minor groove to recognize the 5′-TAAT-3′ core motif (zheng2024transcriptionalprecisionin pages 8-10). The consensus binding motif is 5′-TAATCC-3′ (zheng2024transcriptionalprecisionin pages 10-11). Mutations at different positions produce fundamentally different pathogenic effects—R90 stabilizes the DNA-binding structure through intramolecular interactions rather than direct DNA contact, while K88 and E80 contribute to binding selectivity and specificity (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8).

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

  • Nucleus: CRX functions as a nuclear transcription factor
  • Photoreceptor outer segments: Failure to form properly in severe variants
  • GO Cellular Component terms: GO:0005634 (nucleus), GO:0001750 (photoreceptor outer segment)

Localization

8. Temporal Development

Onset

Progression

  • Generally progressive retinal degeneration
  • Disease course: Chronic, lifelong
  • Cone degeneration typically precedes rod degeneration (sun2023diseasecausingmutationsin pages 5-7)
  • Rate of progression is variable and depends on the specific CRX variant class
  • Truncating effector-domain variants (e.g., E168d2) show relatively rapid photoreceptor degeneration, while extended-domain variants (e.g., CrxRip) may show preserved retinal structure despite severe functional impairment for prolonged periods (zheng2024transcriptionalprecisionin pages 6-7)

Critical Periods

  • Photoreceptor terminal differentiation during retinal development represents a critical window
  • Photoreceptors retain some neuroplasticity for therapeutic intervention, though rescue effects remain partial in preclinical models (sun2023geneaugmentationfor pages 3-4)

9. Inheritance and Population

Epidemiology

  • CRX mutations account for 0.6–2.35% of LCA cases (winkler2020largeanimalmodels pages 12-14)
  • CRX is described as a common cone-rod dystrophy (CRD) causative gene (loukovitis2021areviewof pages 9-11)
  • Inherited retinal diseases as a group affect approximately 1 in 2,000 to 1 in 4,000 people globally
  • The overall prevalence of CRX-specific retinopathy is ultra-rare, though precise population-based prevalence data are not available

Inheritance

Population Demographics

  • CRX mutations have been reported across diverse ethnic populations including Caucasian, Japanese, Chinese, Korean, Mexican, Pakistani, and Indian populations
  • No clear ethnic predilection has been established
  • Male predominance was noted in the bifocal degeneration subset (6/6 cases male in Lin et al. 2025) (lin2025bifocalretinaldegeneration pages 2-4)

10. Diagnostics

Clinical Tests

Electrophysiology (MAXO:0000932): - Full-field ERG (ISCEV standard): Reveals cone or cone-rod dysfunction patterns; markedly delayed b-waves in many cases with a post-phototransduction locus (lin2025bifocalretinaldegeneration pages 2-4) - Pattern ERG (PERG): Bilaterally subnormal P50 responses indicating macular dysfunction (lin2025bifocalretinaldegeneration pages 2-4)

Imaging: - SD-OCT: Demonstrates central outer retinal disruption, thinning of the outer nuclear layer, and retinal disorganization (lin2025bifocalretinaldegeneration pages 4-6) - Ultra-widefield fundus autofluorescence (FAF): Identifies patterns of retinal degeneration including the distinctive bifocal pattern; more sensitive than clinical examination for detecting nasal peripheral degeneration (lin2025bifocalretinaldegeneration pages 4-6, lin2025bifocalretinaldegeneration pages 2-4) - Fundus photography: Shows macular atrophy, pigmentary changes, and peripheral retinal abnormalities

Genetic Testing

Differential Diagnosis

  • Other forms of LCA (LCA1-LCA19, caused by GUCY2D, RPE65, CRB1, CEP290, etc.)
  • Other forms of cone-rod dystrophy (caused by ABCA4, GUCY2D, RPGR, etc.)
  • Retinitis pigmentosa (>80 causative genes)
  • Distinguishing features: Bifocal nasal degeneration pattern, specific ERG profile, and autosomal dominant inheritance help direct genetic testing toward CRX (lin2025bifocalretinaldegeneration pages 6-7)

11. Outcome/Prognosis

Visual Outcomes

  • LCA7: Severe visual impairment from birth/early infancy; poor visual acuity starting within the first year of life (loukovitis2021areviewof pages 9-11)
  • CoRD2: Progressive visual loss; rate depends on variant class
  • Macular dystrophy: May preserve peripheral vision longer

Prognostic Factors

  • Variant class is the strongest prognostic factor: antimorphic and truncating variants cause more severe disease than hypomorphic variants
  • Mutant-to-wildtype CRX protein ratio correlates directly with disease severity (sun2023diseasecausingmutationsin pages 5-7)
  • C-terminus truncation length positively correlates with degree of allelic imbalance and onset of photoreceptor degeneration (zheng2024transcriptionalprecisionin pages 6-7)
  • The disease is not life-threatening but causes significant visual morbidity
  • CRX-related retinopathy does not affect life expectancy

Complications

  • Legal blindness (particularly in LCA7 and severe CoRD)
  • Photophobia and nystagmus (in LCA presentations)
  • Progressive visual field loss
  • Impaired color vision (early cone dysfunction)

12. Treatment

Current Management

No approved pharmacological or gene therapy treatments exist specifically for CRX-related retinopathy. Current management is supportive (MAXO:0000016): - Low vision aids and rehabilitation - Orientation and mobility training - Educational accommodations - Genetic counseling for family planning (MAXO:0000127) - Regular ophthalmological monitoring

Gene Therapy Approaches (Preclinical)

Gene augmentation (MAXO:0001001): - A Tet-On-hCRX inducible system has been developed for proof-of-concept gene augmentation in CRX-null mouse retinas, demonstrating that CRX expression can be induced and that photoreceptors retain neuroplasticity for therapeutic intervention, though rescue effects remain partial (sun2023geneaugmentationfor pages 3-4, sun2023geneaugmentationfor pages 4-6) - AAV2/5-mediated gene augmentation has been tested using photoreceptor-specific promoters (CRX or GRK promoters) with efficient transduction in neonatal mice (sun2023geneaugmentationfor pages 4-6) - AAV-mediated gene therapy has been tested in patient iPSC-derived retinal organoids for dominant CRX-LCA, demonstrating feasibility of rescue in human tissue models (agarwal2026retinalorganoidscurrent pages 42-44)

Gene editing: - CRISPR/Cas9-based approaches for knocking out mutant CRX alleles are under investigation (sun2023geneaugmentationfor pages 4-6) - Suppression-and-replacement strategies may be applicable for dominant-negative variants

Combination therapies: - Anti-apoptotic and neuroprotective agents have been explored as adjunctive therapies (sun2023geneaugmentationfor pages 4-6) - Nr2e3 gene therapy has been investigated as a broad-spectrum approach that resets transcription factor networks including CRX-regulated genes in multiple RP models

Challenges for Gene Therapy

Clinical Trials

No active clinical trials specifically targeting CRX-related retinopathy were identified in ClinicalTrials.gov searches. Treatment development remains at the preclinical stage.

13. Prevention

Primary Prevention

  • No primary prevention measures exist for this genetic condition
  • Genetic counseling (MAXO:0000127) is essential given the autosomal dominant inheritance and high de novo mutation rate

Secondary Prevention (Screening)

  • Cascade genetic testing of family members when a pathogenic CRX variant is identified in a proband
  • Prenatal genetic testing and preimplantation genetic diagnosis (PGD) are available for families with known CRX mutations
  • Recognizing distinctive phenotypic patterns (e.g., bifocal nasal degeneration) can expedite molecular diagnosis (lin2025bifocalretinaldegeneration pages 6-7)

Tertiary Prevention

  • Regular ophthalmological monitoring to track disease progression
  • Low vision rehabilitation to optimize remaining visual function
  • Psychosocial support

14. Other Species / Natural Disease

Naturally Occurring Animal Models

  • CrxRdy cat (Felis catus): A spontaneously occurring model carrying a heterozygous 1-bp deletion in CRX causing a Class III antimorphic frameshift/nonsense mutation. Heterozygous CrxRdy/+ cats exhibit severe cone-led retinal dystrophy modeling early childhood-onset blindness. This is the earliest documented large animal model for CRX-associated disease (winkler2020largeanimalmodels pages 12-14). The feline retina provides translational advantages over rodent models due to its cone-rich region analogous to the human macula.
  • OMIA: CRX-related retinal degeneration is catalogued in Online Mendelian Inheritance in Animals

15. Model Organisms

A comprehensive set of animal and cellular models has been developed to study distinct CRX pathogenic mechanisms:

Table (click to expand)
Model name/type Species Genetic modification / mutation Phenotype recapitulation (key features) Disease modeled Key findings References
CrxE168d2 knock-in mouse Mouse (Mus musculus) Knock-in of human-equivalent c.503_504del (p.Glu168fs) truncating effector-domain variant Heterozygotes retain only 6–8 ONL rows by 3 months, have no detectable cone function, severely impaired rod function by 1 month, and complete rod function loss by 3 months; homozygotes have 3–4 ONL rows by 1 month and never develop visual function Dominant LCA7 / severe early-onset CRX retinopathy Demonstrated that C-terminal truncating variants act largely through dominant-negative effects with allelic overexpression of mutant transcript/protein, increasing mutant:WT ratio and disrupting downstream photoreceptor gene regulation (zheng2024transcriptionalprecisionin pages 6-7)
CrxRip mouse Mouse (Mus musculus) Spontaneous c.763del (p.Gly255Alafs*133) frameshift causing extended non-homologous C-terminus Completely blind at 1 month, but ONL thickness largely preserved up to at least 18 months; incomplete photoreceptor differentiation and severe functional loss without rapid structural degeneration Congenital blindness / LCA-like CRX-associated retinopathy Showed that extended effector-domain variants can cause severe dysfunction by altering cofactor recruitment and transcriptional regulation, distinct from rapid-degeneration truncation models (zheng2024transcriptionalprecisionin pages 6-7, zheng2024transcriptionalprecisionin pages 7-8)
CrxR90W knock-in mouse Mouse (Mus musculus) Knock-in p.Arg90Trp homeodomain missense variant Phenotype similar to Crx-null retina in homozygotes, with major photoreceptor dysfunction/degeneration due to failure of normal terminal differentiation Recessive LCA and mild late-onset dominant CoRD Established a hypomorphic mechanism: markedly reduced DNA-binding affinity and weak transactivation of photoreceptor promoters; severity tracks with loss of DNA-binding strength (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8)
CrxE80A knock-in mouse Mouse (Mus musculus) Knock-in p.Glu80Ala homeodomain missense variant No detectable cone-mediated responses, defective rod-mediated responses at 1 month, shortened outer segments, ONL disorganization, but no obvious early photoreceptor degeneration Severe early-onset dominant cone-rod dystrophy Demonstrated a gain-of-function / antimorphic mechanism in which CRX retains target preference but loses selectivity, causing promiscuous binding and hyperactivation of early target genes with developmental asynchrony (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 7-8)
CrxK88N knock-in mouse Mouse (Mus musculus) Knock-in p.Lys88Asn homeodomain missense variant Severe dominant retinopathy phenotype in knock-in models; mechanistically distinct from hypomorphic variants Severe dominant CoRD/LCA-spectrum retinopathy Showed that some homeodomain mutants alter DNA-binding specificity rather than merely affinity, redirecting CRX to ectopic non-cognate sites and severely perturbing the photoreceptor gene network (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 10-11, zheng2024transcriptionalprecisionin pages 13-13)
Crx knockout mouse Mouse (Mus musculus) Crx null / deletion Photoreceptors are produced, but phototransduction gene expression is reduced; heterozygous deletion produces only very mild phenotypes Loss-of-function reference model for CRX deficiency Important comparator showing that haploinsufficiency alone is usually insufficient to explain severe dominant CRX disease; therefore not an ideal model for dominant CRX retinopathies (langouet2022mutationsinbcora pages 1-2, zheng2024transcriptionalprecisionin pages 6-7)
CrxRdy cat (spontaneous model) Cat (Felis catus) Spontaneous 1-bp deletion causing truncating Class III CRX mutation with intact DNA-binding domain but defective transactivation Severe cone-led retinal dystrophy / early childhood-onset blindness analog; documented as a spontaneous large-animal model LCA7 / severe CRX-associated retinal degeneration Earliest documented large-animal CRX model; supported allelic overexpression and truncation-based pathogenicity, and provides translational advantages because feline retina better approximates human cone-rich specializations than rodent retina (winkler2020largeanimalmodels pages 12-14, zheng2024transcriptionalprecisionin pages 6-7)
CRX monoallelic knockout retinal organoids Human retinal organoids Monoallelic CRX knockout / haploinsufficiency in hESC-derived retinal organoids Delayed ONL stratification, thinner ONL, major loss of outer segments, downregulation of phototransduction and inner/outer-segment genes; arrested translocation of CRX+ precursors and actomyosin over-tension during early differentiation Dominant CRX-associated retinopathy due to haploinsufficiency Provided direct human-model evidence that CRX haploinsufficiency can impair precursor translocation and differentiation, revealing a pathogenic mechanism not fully captured in mouse systems (sun2023geneaugmentationfor pages 3-4, zheng2024transcriptionalprecisionin pages 1-2)
CRX-LCA patient iPSC-derived retinal organoids Human iPSC-derived retinal organoids Patient-derived organoids carrying dominant CRX-LCA mutation(s) Retinal organoid phenotypes used to assess rescue of photoreceptor development/function in a human context Dominant CRX-LCA Demonstrated feasibility of testing AAV-mediated gene therapy in patient stem-cell-derived retinal tissue; supports organoids as a precision preclinical platform for CRX therapeutic development (zheng2024transcriptionalprecisionin pages 13-13, agarwal2026retinalorganoidscurrent pages 42-44)
Tet-On-hCRX transgenic augmentation model Mouse (Mus musculus) Inducible human CRX transgene under Tet-On control for augmentation in mutant/null CRX backgrounds Allows quantitative and temporal control of augmented CRX during the developmental window; CRX expression inducible in null retinae Preclinical therapeutic model for CRX-associated retinopathies Proof-of-concept model showing photoreceptors retain neuroplasticity and can respond to CRX augmentation, though rescue is partial; informed development of AAV2/5 photoreceptor-directed augmentation strategies (sun2023geneaugmentationfor pages 3-4, sun2023geneaugmentationfor pages 4-6, sun2023geneaugmentationfor pages 7-10)

Table: This table summarizes the principal animal and cellular models used to study CRX-related retinopathy, spanning mouse, cat, and human organoid systems. It highlights how each model captures distinct mechanisms such as haploinsufficiency, dominant-negative truncation, and altered DNA-binding specificity, and why these models are useful for therapeutic development.

Key Findings from Models

Summary

CRX-related retinopathy is a clinically heterogeneous group of inherited retinal dystrophies caused by mutations in the CRX transcription factor gene. Over 25 years of research have established four distinct pathogenic variant classes, each with well-characterized molecular mechanisms ranging from dominant-negative effects through altered DNA binding specificity to haploinsufficiency. The disease spectrum encompasses LCA7, CoRD2, RP, and macular dystrophy, with most cases following autosomal dominant inheritance with frequent de novo occurrence. Diagnosis relies on electrophysiology (ERG, PERG), multimodal retinal imaging (OCT, ultra-widefield autofluorescence), and molecular genetic testing. No approved treatments exist, but preclinical gene augmentation and gene editing approaches show promise, with AAV-mediated delivery and CRISPR-based strategies under active investigation. The development of multiple knock-in mouse models, the CrxRdy cat model, and human retinal organoid systems continues to advance understanding of disease mechanisms and therapeutic development. Systems biology approaches integrating CRX intrinsic activities, protein interactions, and chromatin environment are expected to accelerate precision medicine for CRX-linked diseases (zheng2024transcriptionalprecisionin pages 8-10, zheng2024transcriptionalprecisionin pages 1-2, zheng2024transcriptionalprecisionin pages 10-11).

References

  1. (sun2023geneaugmentationfor pages 1-3): Chi Sun and Shiming Chen. Gene augmentation for autosomal dominant crx-associated retinopathies. Advances in experimental medicine and biology, 1415:135-141, Jan 2023. URL: https://doi.org/10.1007/978-3-031-27681-1_21, doi:10.1007/978-3-031-27681-1_21. This article has 8 citations and is from a peer-reviewed journal.

  2. (zheng2024transcriptionalprecisionin pages 1-2): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  3. (zheng2024transcriptionalprecisionin pages 4-6): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  4. (sun2023diseasecausingmutationsin pages 5-7): Chi Sun and Shiming Chen. Disease-causing mutations in genes encoding transcription factors critical for photoreceptor development. Frontiers in Molecular Neuroscience, Apr 2023. URL: https://doi.org/10.3389/fnmol.2023.1134839, doi:10.3389/fnmol.2023.1134839. This article has 18 citations.

  5. (loukovitis2021areviewof pages 9-11): Eleftherios Loukovitis, Stoimeni Anastasia, Paris Tranos, Miltos Balidis, Solon Asteriadis, Vakalis Thanos, Sousouras Thanos, and George Anogeianakis. A review of recent developments in retinitis pigmentosa genetics, its clinical features, and natural course. Medical Hypothesis, Discovery & Innovation in Ophthalmology, Feb 2021. URL: https://doi.org/10.51329/mehdiophthal1410, doi:10.51329/mehdiophthal1410. This article has 11 citations.

  6. (lin2025bifocalretinaldegeneration pages 2-4): Siying Lin, Gavin Arno, Anthony G. Robson, Elena R. Schiff, Moin D. Mohamed, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Bifocal retinal degeneration observed on ultra-widefield autofluorescence in some cases of crx-associated retinopathy. Eye, 39:951-957, Dec 2025. URL: https://doi.org/10.1038/s41433-024-03522-2, doi:10.1038/s41433-024-03522-2. This article has 3 citations and is from a peer-reviewed journal.

  7. (winkler2020largeanimalmodels pages 12-14): Paige A. Winkler, Laurence M. Occelli, and Simon M. Petersen-Jones. Large animal models of inherited retinal degenerations: a review. Cells, 9:882, Apr 2020. URL: https://doi.org/10.3390/cells9040882, doi:10.3390/cells9040882. This article has 94 citations.

  8. (lin2025bifocalretinaldegeneration pages 6-7): Siying Lin, Gavin Arno, Anthony G. Robson, Elena R. Schiff, Moin D. Mohamed, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Bifocal retinal degeneration observed on ultra-widefield autofluorescence in some cases of crx-associated retinopathy. Eye, 39:951-957, Dec 2025. URL: https://doi.org/10.1038/s41433-024-03522-2, doi:10.1038/s41433-024-03522-2. This article has 3 citations and is from a peer-reviewed journal.

  9. (sun2023diseasecausingmutationsin pages 4-5): Chi Sun and Shiming Chen. Disease-causing mutations in genes encoding transcription factors critical for photoreceptor development. Frontiers in Molecular Neuroscience, Apr 2023. URL: https://doi.org/10.3389/fnmol.2023.1134839, doi:10.3389/fnmol.2023.1134839. This article has 18 citations.

  10. (zheng2024transcriptionalprecisionin pages 8-10): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  11. (zheng2024transcriptionalprecisionin pages 6-7): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  12. (zheng2024transcriptionalprecisionin pages 7-8): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  13. (sun2023geneaugmentationfor pages 3-4): Chi Sun and Shiming Chen. Gene augmentation for autosomal dominant crx-associated retinopathies. Advances in experimental medicine and biology, 1415:135-141, Jan 2023. URL: https://doi.org/10.1007/978-3-031-27681-1_21, doi:10.1007/978-3-031-27681-1_21. This article has 8 citations and is from a peer-reviewed journal.

  14. (zheng2024transcriptionalprecisionin pages 10-11): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  15. (zheng2024transcriptionalprecisionin pages 15-15): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  16. (sun2023diseasecausingmutationsin pages 1-2): Chi Sun and Shiming Chen. Disease-causing mutations in genes encoding transcription factors critical for photoreceptor development. Frontiers in Molecular Neuroscience, Apr 2023. URL: https://doi.org/10.3389/fnmol.2023.1134839, doi:10.3389/fnmol.2023.1134839. This article has 18 citations.

  17. (zheng2024transcriptionalprecisionin pages 3-4): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  18. (zheng2024transcriptionalprecisionin pages 11-12): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  19. (langouet2022mutationsinbcora pages 1-2): Maéva Langouët, Christine Jolicoeur, Awais Javed, Pierre Mattar, Micah D. Gearhart, Stephen P. Daiger, Mette Bertelsen, Lisbeth Tranebjærg, Nanna D. Rendtorff, Karen Grønskov, Catherine Jespersgaard, Rui Chen, Zixi Sun, Hui Li, Najmeh Alirezaie, Jacek Majewski, Vivian J. Bardwell, Ruifang Sui, Robert K. Koenekoop, and Michel Cayouette. Mutations inbcor, a co-repressor ofcrx/otx2, are associated with early-onset retinal degeneration. Sep 2022. URL: https://doi.org/10.1126/sciadv.abh2868, doi:10.1126/sciadv.abh2868. This article has 13 citations and is from a highest quality peer-reviewed journal.

  20. (lin2025bifocalretinaldegeneration pages 4-6): Siying Lin, Gavin Arno, Anthony G. Robson, Elena R. Schiff, Moin D. Mohamed, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Bifocal retinal degeneration observed on ultra-widefield autofluorescence in some cases of crx-associated retinopathy. Eye, 39:951-957, Dec 2025. URL: https://doi.org/10.1038/s41433-024-03522-2, doi:10.1038/s41433-024-03522-2. This article has 3 citations and is from a peer-reviewed journal.

  21. (sun2023geneaugmentationfor pages 4-6): Chi Sun and Shiming Chen. Gene augmentation for autosomal dominant crx-associated retinopathies. Advances in experimental medicine and biology, 1415:135-141, Jan 2023. URL: https://doi.org/10.1007/978-3-031-27681-1_21, doi:10.1007/978-3-031-27681-1_21. This article has 8 citations and is from a peer-reviewed journal.

  22. (agarwal2026retinalorganoidscurrent pages 42-44): Renu Agarwal, Igor Iezhitsa, Jose R. Hombrebueno, and Puneet Agarwal. Retinal organoids: current status of development and new avenues for application in disease modeling, drug discovery and therapeutics. International Journal of Retina and Vitreous, May 2026. URL: https://doi.org/10.1186/s40942-026-00846-x, doi:10.1186/s40942-026-00846-x. This article has 1 citations.

  23. (zheng2024transcriptionalprecisionin pages 13-13): Yiqiao Zheng and Shiming Chen. Transcriptional precision in photoreceptor development and diseases – lessons from 25 years of crx research. Frontiers in Cellular Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fncel.2024.1347436, doi:10.3389/fncel.2024.1347436. This article has 9 citations.

  24. (sun2023geneaugmentationfor pages 7-10): Chi Sun and Shiming Chen. Gene augmentation for autosomal dominant crx-associated retinopathies. Advances in experimental medicine and biology, 1415:135-141, Jan 2023. URL: https://doi.org/10.1007/978-3-031-27681-1_21, doi:10.1007/978-3-031-27681-1_21. This article has 8 citations and is from a peer-reviewed journal.

Artifacts